A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed
A critical look at the early stage BMS oncology pipeline
Looking beyond CAR-T cells and checkpoint blockade, there are some promising young companies on the rise to watch out for - here's one of them
Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.
Update on Kura Oncology's progress with tipifarnib and their emerging pipeline
What's in store on the penultimate day of JPM20?
Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco
Highlights and lowlights from Day 1 of JPM20
Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.
We take a look at several key developments in myeloma on the antibody and cell therapy front.
Some examples of potentially useful biomarker inclusion in early oncology trials
Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy
Drugging the undruggable with creative approaches to molecule development
Commentary on some up and coming biotechs in the oncology space
Insights and commentary from the second day at #JPM19
Commentary on Day 3 at 2018 JP Morgan Healthcare Conference in San Francisco
A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours
Insights and commentary from the first day of JPM19
Interview with Syros Pharma CEO Dr Nancy Simonian
Commentary on Day 2 of the 2018 JP Morgan Healthcare Conference in San Francisco
Commentary on Day 1 of the 2018 JP Morgan Healthcare Conference in San Francisco
Update on Neon Tx as they move into commercial new product development with their neoantigen platform.
Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens
First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.
Commentary on Wednesday at JPM17 in San Francisco
Commentary on Day 2 of the 2017 JP Morgan Healthcare Conference in San Francisco
Commentary around some of the corporate presentations at Day 1 of the 2017 JP Morgan Healthcare conference in San Francisco.
Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL
A look at some promising agents in new product development emerging in early CLL trials
How are recently approved novel therapies impacting the CLL landscape and where are we going next?
A look at the latest data for a CD79b targeted ADC in lymphomas
A look at the emerging trends we can expect in 2017 for cancer research
An in-depth look at the sudden and unexpected announcement underlying the clinical hold for Seattle Genetics anti-CD33 ADC Vadastuximab Talirine in AML.
A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18
Two biotech companies are in a race to market for a novel target in advanced prostate cancer.
Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco
Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.
Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.
An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.
Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.
Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?
What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.
Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.
There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging
Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.
Update from JP Morgan Healthcare 2014 on Clovis Oncology and AstraZeneca race to market with new drugs for treatment of T790M positive non-small cell lung cancer.
Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma.
Will they be successful despite the huge complexity involved in the underlying processes?
Increasingly, we are seeing the evolution of diagnostic tests in cancer research. Foundation Medicine are using their gene sequencing platform to identify actionable mutations and assist oncologists make better treatment decisions for their patients.
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies.
At ASH, the impressive data from adult and pediatric ALL was presented.
This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.
The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?